Bitwise Avalanch Aktie - BAVA

Common Shares of Beneficial Interest of Bitwise Avalanche (BAVA) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

( - )

Gebot

Fragen

Volumen

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Handelsende

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has...

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

COPENHAGEN, Denmark, June 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a government...

Bitwise Launches Spot Avalanche ETP (BAVA); Includes In-House Staking To Maximize Staking Rewards and Oversight

Bitwise Launches Spot Avalanche ETP (BAVA); Includes In-House Staking To Maximize Staking Rewards and...

Bavarian Nordic's IMVANEX(r) Smallpox Vaccine Receives Positive Opinion From European Regulatory Authorities

KVISTGAARD, Denmark, May 31, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) announced today that the Committee for Medicinal Products...

Bavarian Nordic Establishes a Sponsored Level 1 ADR Program in the US

KVISTGAARD, Denmark, May 29, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) announced today that it has established a sponsored Level 1...

Bavarian Nordic's CV-301 Cancer Immunotherapy Candidate Shows Promise in Colorectal Cancer

MOUNTAIN VIEW, Calif., May 29, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic (OMX:BAVA) announced today that promising data from a Phase 2 trial of...

Bavarian Nordic Announces Presentation of PROSTVAC(R) at the 2013 ASCO Annual Meeting

KVISTGAARD, Denmark, May 27, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA) announced today that a new planned trial of PROSTVAC® in...

Bavarian Nordic Reports First Quarter 2013 Results

KVISTGAARD, Denmark, May 16, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) today publishes its first quarter 2013 results. Revenue for...

Bavarian Nordic Receives Contract Valued Up to USD 228 Million From the U.S. Government Securing Continued Production and Deliv

KVISTGAARD, Denmark, April 16, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) announced today that BARDA (Biomedical Advanced Research...

Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Phase 3 Trial

KVISTGAARD, Denmark, April 8, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA) today announced that the Company plans to conduct an...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

BAVA - Frequently Asked Questions (FAQ)

What is the current Common Shares of Beneficial Interest of Bitwise Avalanche share price?

The current share price of Common Shares of Beneficial Interest of Bitwise Avalanche is US$ 0,00

What is the 1 year trading range for Common Shares of Beneficial Interest of Bitwise Avalanche share price?

Common Shares of Beneficial Interest of Bitwise Avalanche has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Common Shares of Beneficial Interest of Bitwise Avalanche (BAVA)

Common Shares of Beneficial Interest of Bitwise Avalanche (BAVA) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

BAVA Neueste Nachrichten

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Bitwise Launches Spot Avalanche ETP (BAVA); Includes In-House Staking To Maximize Staking Rewards and Oversight

Bavarian Nordic's IMVANEX(r) Smallpox Vaccine Receives Positive Opinion From European Regulatory Authorities

Bavarian Nordic Establishes a Sponsored Level 1 ADR Program in the US

Bavarian Nordic's CV-301 Cancer Immunotherapy Candidate Shows Promise in Colorectal Cancer

Bavarian Nordic Announces Presentation of PROSTVAC(R) at the 2013 ASCO Annual Meeting

Bavarian Nordic Reports First Quarter 2013 Results

Bavarian Nordic Receives Contract Valued Up to USD 228 Million From the U.S. Government Securing Continued Production and Deliv

Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Phase 3 Trial

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Bitwise Launches Spot Avalanche ETP (BAVA); Includes In-House Staking To Maximize Staking Rewards and Oversight

BAVA - Frequently Asked Questions (FAQ)

BAVA Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Common Shares of Beneficial Interest of Bitwise Avalanche (BAVA)

Common Shares of Beneficial Interest of Bitwise Avalanche (BAVA) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

BAVA Neueste Nachrichten

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Bitwise Launches Spot Avalanche ETP (BAVA); Includes In-House Staking To Maximize Staking Rewards and Oversight

Bavarian Nordic's IMVANEX(r) Smallpox Vaccine Receives Positive Opinion From European Regulatory Authorities

Bavarian Nordic Establishes a Sponsored Level 1 ADR Program in the US

Bavarian Nordic's CV-301 Cancer Immunotherapy Candidate Shows Promise in Colorectal Cancer

Bavarian Nordic Announces Presentation of PROSTVAC(R) at the 2013 ASCO Annual Meeting

Bavarian Nordic Reports First Quarter 2013 Results

Bavarian Nordic Receives Contract Valued Up to USD 228 Million From the U.S. Government Securing Continued Production and Deliv

Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Phase 3 Trial

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Bitwise Launches Spot Avalanche ETP (BAVA); Includes In-House Staking To Maximize Staking Rewards and Oversight

BAVA - Frequently Asked Questions (FAQ)

BAVA Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS